Detection
In the past, most cases of genital herpes in the United States have been caused by infection with HSV-2. Adequate evidence suggests that the most widely used, currently available serologic screening test for HSV-2 approved by the US Food and Drug Administration is not suitable for population-based screening, based on its low specificity, the lack of widely available confirmatory testing, and its high false-positive rate. Rates of genital herpes due to HSV-1 infection in the United States may be increasing. While HSV-1 infection can be identified by serologic tests, the tests cannot determine if the site of infection is oral or genital; thus, these serologic tests are not useful for screening for asymptomatic genital herpes resulting from HSV-1 infection.
Benefits of Early Detection and Intervention
Based on limited evidence from a small number of trials on the potential benefit of screening and interventions in asymptomatic populations and an understanding of the natural history and epidemiology of genital HSV infection, the USPSTF concluded that the evidence is adequate to bound the potential benefits of screening in asymptomatic adolescents and adults, including those who are pregnant, as no greater than small.
Harms of Early Detection and Intervention
Based on evidence on potential harms from a small number of trials, the high false-positive rate of the screening tests, and the potential anxiety and disruption of personal relationships related to diagno- The USPSTF recommends the service. There is high certainty that the net benefit is substantial. Offer or provide this service.
Suggestions for Practice B
The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or there is moderate certainty that the net benefit is moderate to substantial.
Offer or provide this service.
C
The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small.
Offer or provide this service for selected patients depending on individual circumstances.
D
The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.
Discourage the use of this service.
I statement
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.
Read the Clinical Considerations section of the USPSTF Recommendation
Statement. If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.
USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the results of future studies.
Moderate
The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as the number, size, or quality of individual studies. inconsistency of findings across individual studies. limited generalizability of findings to routine primary care practice. lack of coherence in the chain of evidence. As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion.
The USPSTF defines certainty as "likelihood that the USPSTF assessment of the net benefit of a preventive service is correct." The net benefit is defined as benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature of the overall evidence available to assess the net benefit of a preventive service.
Low
The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of the limited number or size of studies. important flaws in study design or methods. inconsistency of findings across individual studies. gaps in the chain of evidence. findings not generalizable to routine primary care practice. lack of information on important health outcomes. More information may allow estimation of effects on health outcomes. sis, the USPSTF found that the evidence is adequate to bound the potential harms of screening in asymptomatic adolescents and adults, including those who are pregnant, as at least moderate.
USPSTF Assessment
The USPSTF concludes with moderate certainty that the harms outweigh the benefits for population-based screening for genital HSV infection in asymptomatic adolescents and adults, including those who are pregnant.
Clinical Considerations

Patient Population Under Consideration
This recommendation statement applies to asymptomatic adolescents and adults, including those who are pregnant, without a history of genital HSV infection ( Figure 2 ).
Screening Tests
The USPSTF does not recommend serologic screening for genital HSV infection in asymptomatic persons.
Treatment
The CDC provides guidance for the diagnosis and management of genital HSV infection. 2
Additional Approaches to Prevention
The USPSTF recommends intensive behavioral counseling interventions to reduce the likelihood of acquiring an STI for all sexually active adolescents and for adults at increased risk. 3 
Useful Resources
The USPSTF has issued recommendations on screening for other STIs, including chlamydia and gonorrhea, 4 hepatitis B virus, 5 human immunodeficiency virus (HIV), 6 and syphilis. 7 
Other Considerations
Research Needs and Gaps
There are many areas in need of research to better understand the detection and management of asymptomatic genital HSV infection, including • Improved epidemiologic data on the true prevalence and natural history of asymptomatic genital HSV infection in the United States For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to https://www.uspreventiveservicestaskforce.org.
The most widely used, currently available serologic screening test for HSV-2 is not suitable for population-based screening, based on its low specificity, the lack of widely available confirmatory testing, and its high false-positive rate. While serologic screening tests can detect HSV-1 infection, the tests cannot determine if the site of infection is oral or genital.
There is no cure for genital HSV infection. Antiviral medications are used for the management of symptomatic outbreaks and for prevention in patients with a history of frequent symptomatic outbreaks.
The USPSTF recommends intensive behavioral counseling interventions to reduce the likelihood of acquiring a sexually transmitted infection for all sexually active adolescents and for adults at increased risk. The USPSTF has also issued recommendations on screening for other sexually transmitted infections, including chlamydia and gonorrhea, hepatitis B virus, HIV, and syphilis. These recommendations are available on the USPSTF website (https://www.uspreventiveservicestaskforce.org).
Genital herpes is an STI caused by 2 related viruses, HSV-1 and HSV-2.
In adolescents and adults, genital infection often results in outbreaks of blisters (vesicles) in the area in and around the genitals and rectum. These blisters break and leave sores (ulcers) that are often painful. The first outbreak of genital herpes is usually the most painful and may be accompanied by flu-like symptoms, including fever, body aches, and swollen glands. Among persons who have a symptomatic first outbreak, 70% to 90% will have at least 1 more symptomatic outbreak within the first year, with an average of 4 outbreaks. 8, 9 Repeat outbreaks are usually shorter and less severe than the initial outbreak. Although the risk of transmission is higher during a symptomatic outbreak, persons with genital herpes can spread the infection to sexual partners even when they are asymptomatic. Studies suggest that up to 85% of persons who are found to be infected with HSV-2 and who report no prior symptoms of genital herpes have a symptomatic outbreak within 6 months of being tested. According to some experts, persons who receive education about genital herpes may be more likely to recognize and report its symptoms. If this is true, some persons who are considered "asymptomatic" may have actually experienced symptoms but not identified them as genital herpes. There is currently no cure for genital herpes; once infection has occurred, the virus remains in a person for life. For this reason, the prevalence of infection increases with age. Data from the 2005-2010 National Health and Nutrition Examination Survey indicate that the prevalence of HSV-2 infection ranged from 1.2% in adolescents aged 14 to 19 years to 25.6% in adults aged 40 to 49 years. 10 Overall, 15.7% of persons aged 14 to 49 years in the United States tested positive for HSV-2 infection between 2005 and 2010. 10 These estimates, however, should be interpreted with caution; because of a lack of confirmatory testing, these data may overestimate the prevalence of HSV-2 infection. These data also may underestimate the overall prevalence of genital herpes, as they do not account for herpes infection caused by HSV-1. In the National Health and Nutrition Examination Survey, women were almost twice as likely to be infected with HSV-2 as men (20.9% vs 11.5%), in part because of anatomical factors that predispose women to infection. 11 Rates of HSV-2 infection also vary by race/ethnicity and geographical region and are higher in men who have sex with men. 10 The herpes simplex virus may be transmitted from mother to infant during vaginal delivery. Among women with a prior history of symptomatic genital herpes, nearly 75% will have at least 1 recurrence during pregnancy and about 14% will have symptoms or clinical recurrence at the time of delivery. 12, 13 Evidence shows, however, that vertical transmission and subsequent severe neonatal HSV infection are most likely in pregnant women who develop the initial genital infection during pregnancy. 14, 15 The overall incidence of neonatal herpes is low. 14, 16 Older data from a 2006 study using a multistate pediatric inpatient discharge database estimated the incidence of neonatal HSV infection as 9.6 cases per 100 000 births (95% CI, 4.3-12.0). 16 The most recent estimate of neonatal herpes incidence comes from a large study in New York City of cases reported between 2006 and 2010. Using a clinical laboratory system, that study found 76 cases of neonatal HSV infection among approximately 571 000 infants-an estimated incidence rate of 13.3 cases per 100 000 live births. 17 The study also found that of the 72% of cases for which HSV typing was done, infections were almost equally caused by HSV-1 and HSV-2 (28 vs 27 cases). 17 Incidence rates are thought to vary by geographic region and race/ethnicity. In the multistate study, incidence rates were substantially higher in infants born to women covered by Medicaid (15.1 cases per 100 000 live births) vs private insurance (5.4 cases per 100 000 live births). 16, 18 Approximately 45% of infants with neonatal HSV infection develop relatively mild skin, eye, or mucous membrane infections; 30% develop a central nervous system infection; and 25% develop disseminated disease. 19 Four percent of infants with a central nervous system infection and 30% of infants with disseminated disease may die as a result. 20 
Scope of Review
The USPSTF commissioned a systematic evidence review to examine the evidence on the accuracy, benefits, and harms of serologic screening for HSV-2 infection in asymptomatic adolescents and adults, including those who are pregnant. 21, 22 The evidence review also considered the effectiveness and harms of preventive medications and behavioral counseling interventions in asymptomatic populations to reduce future symptomatic episodes and transmission to susceptible sexual partners and infants.
Accuracy of Screening Tests
HerpeSelect (Focus Diagnostics), the most widely available serologic test for genital HSV-2 infection approved by the US Food and Drug Administration, has a pooled estimate of sensitivity of 99% (95% CI, 97%-100%) and a pooled estimate of specificity of 83% (95% CI, 72%-91%). 22 A second test, the biokit HSV-2 Rapid Test (Biokit USA), has a pooled estimate of sensitivity of 84% (95% CI, 73%-91%) and specificity of 95% (95% CI, 93%-97%). 22 In the general US population, the positive predictive value may be as low as 75% for the biokit test and as low as 50% for HerpeSelect. Western blot is considered to be the gold standard for the serologic diagnosis of herpes. Western blot test results can be obtained by sending a blood sample to a single research laboratory (University of Washington Clinical Virology Laboratory); however, this test is not widely available as a screening or confirmatory test for persons who screen positive for HSV-2 on one of the less-specific, commercially available serologic tests. No studies have examined the screening accuracy of serologic HSV tests in pregnant women. Serologic HSV tests may be clinically useful for persons with persistent undiagnosed genital symptoms and in other diagnostic settings.
Effectiveness of Early Detection and Treatment
Currently, there is no cure for genital HSV infection. Antiviral medications are generally used for the management of symptomatic outbreaks and for prevention in patients with a history of frequent symptomatic outbreaks. In studies, many persons identified with asymptomatic genital herpes (ie, they have been infected with HSV-2 and have never experienced symptoms) have a symptomatic outbreak within 6 months of testing. The increasing percentage of genital herpes cases caused by HSV-1 also limits the potential benefit of serologic screening in asymptomatic persons. While HSV-1 infection can be detected through serologic tests, these tests cannot determine the site of HSV infection. Since HSV-1 can cause both oral and genital herpes infections, and oral herpes infection is very common, serologic tests for HSV-1 cannot be used to screen for asymptomatic genital herpes infection. The evidence is inadequate to determine if suppressive antiviral therapy reduces transmission of genital HSV infection between serodiscordant couples with an asymptomatic partner.
Pregnant adolescents and women with new or known history of genital HSV infection should be carefully observed during pregnancy. To reduce the chance of HSV transmission to the infant during delivery, women with active genital HSV lesions at the time of birth are usually offered the option of cesarean delivery. No studies have examined the effectiveness of antiviral therapy to decrease the risk for HSV transmission to pregnant women by an infected partner.
Potential Harms of Screening and Treatment
Serologic screening in asymptomatic persons will likely result in a large number of false-positive results. Given the limitations of currently available tests, 1 of 2 positive results may be false. Given the test characteristics of the most widely used serologic screening test for HSV-2 and a population infection prevalence of 15%, screening 10 000 persons would result in approximately 1485 true-positive and 1445 false-positive results. Confirmatory testing is not currently widely available and is only performed at a single research laboratory. There are social and emotional harms of receiving a falsepositive result, in addition to the potential harms of unnecessary treatment with preventive antiviral medications. 23, 24 However, antiviral medications are generally considered to have few harms in nonpregnant adults. 21 
Estimate of Magnitude of Net Benefit
Based on the natural history of HSV infection, its epidemiology, and the available evidence on the accuracy of serologic screening tests, the USPSTF found adequate evidence to bound the potential benefits and harms and conclude with moderate certainty that the harms outweigh the benefits of serologic screening for genital HSV infection in asymptomatic adolescents and adults, including those who are pregnant.
Response to Public Comment
A draft version of this recommendation statement was posted for public comment on the USPSTF website from August 2 to August 29, 2016. The USPSTF reviewed and considered all comments received during this period. Several comments supported the USPSTF's analysis and conclusions; some comments noted that the recommendation is consistent with current clinical practice and advice from other organizations, including the CDC and the American College of Obstetricians and Gynecologists (ACOG). A few comments expressed concern that persons with asymptomatic genital herpes infection can (unknowingly) transmit the infection to sexual partners. While the USPSTF understands this concern, given the current lack of accurate, widely available serologic screening tests and the expected high rate of false-positive results that would occur with widespread screening in asymptomatic persons, the USPSTF continues to recommend against routine serologic screening in asymptomatic adolescents and adults. In addition, the USPSTF clarified its language about HSV-1 infection, noting that while HSV-1 infection can be identified by serologic tests, the tests cannot determine if the site of infection is oral or genital.
Update of Previous USPSTF Recommendation
This recommendation is consistent with and updates the 2005 USPSTF recommendation. 25 The current recommendation is based on substantial new evidence on the limited accuracy of serologic screening tests for genital HSV-2 infection and a small amount of new evidence on the benefits and harms of screening.
Recommendations of Others
The American Academy of Family Physicians, 26 ACOG, 27 and the CDC 2 do not recommend routine serologic screening for genital HSV infection in asymptomatic adolescents or adults. Diagnostic testing, however, in persons with recurrent atypical genital symptoms may be helpful. The CDC recommends consideration of serologic testing for HSV-2 in persons presenting for STI evaluation and for persons living with HIV infection. 2 The CDC also recommends consideration of screening for HSV infection in men who have sex with men and who are at high risk for HIV infection. 2 The American Academy of Family Physicians, 26 ACOG, 28 and the CDC 2 do not recommend routine serologic screening for genital HSV infection in pregnant adolescents and women. The CDC 2 and ACOG 28 recommend asking pregnant women about history of genital HSV infection and consideration of cesarean delivery for women with prodromal symptoms or active genital lesions during labor to reduce the risk of neonatal HSV infection. The CDC recommends that women with recurrent genital herpes during pregnancy be offered suppressive therapy at 36 weeks of gestation. 2 
